All studies
Oncology · EHR · US

Merola 2024

Lung cancer

DAG reportedITT, PPSuperiorityAcademia, Industry3/5 disclosures
Comparisons
1
In the analysis
1
all comparisons pooled
Target trials
1
Emulations reported
1
2 treatments

Comparisons

1 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
12-month overall survival
vs KEYNOTE-189·HR·Efficacy
0.490.38–0.64
0.950.78–1.16
no overlap3.96 SE apart

Design and methods

Estimand
ITT, PP
Design hypothesis
Superiority
Matching / weighting
IPTW
Analysis method
Weighted marginal structural proportional hazards model, Weighted Kaplan-Meier estimator
Missing data
Multiple imputation
Covariates adjusted
23
DAG
Yes
QBA
No

Data and sample

Data type
EHR
Data sources
1
Geography
US
Eligible sample
1854
Treated
589
Control
1265
Emulations
1
Treatments compared
2

Transparency

3/5
Protocol
https://clinicaltrials.gov/study/NCT05908799
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: Industry, Government
COI institutions
Amgen, AbbVie, Bayer Pharmaceuticals, AstraZeneca, Gilead Sciences, Pfizer, Johnson & Johnson, UCB Pharma, Takeda, Boehringer Ingelheim, Veracity Healthcare Analytics, Exponent, MITRE, Greenwich LifeSciences
Funding
Declared: Private
Funders
Amgen, AbbVie, Bayer Pharmaceuticals, AstraZeneca, Gilead Sciences, Pfizer, and Johnson & Johnson

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2024_Merola_LungCancer
DOI
https://dx.doi.org/10.1001/jamanetworkopen.2024.36535
Affiliations
Baylor College of Medicine, Duke-Margolis Center, Amgen, AbbVie, Bayer Pharmaceuticals, AstraZeneca, Gilead Sciences, Pfizer, Johnson & Johnson, COTA Healthcare, Tempus, ConcertAI, TriNetX, xCures, Loopback Analytics
Sector
Academia, Industry
Target trials (study level)
KEYNOTE-189
Registration
NCT02578680